Emma G. Wilmot, United Kingdom

University Hospitals of Derby and Burton NHS FT Diabetes & Endocrinololgy
Emma Wilmot is a Consultant Diabetologist with specialist interests which include Type 1 diabetes, insulin pump therapy and diabetes technology, young adults with diabetes and antenatal diabetes care. She was awarded the University of Leicester medal for excellent PhD performance in 2013 for her PhD “Type 2 diabetes in younger adults” and was appointed as an Honorary (consultant) Assistant Professor at the University of Nottingham in 2018. She is a principal investigator on diabetes research trials. She is the founder of the ABCD Diabetes Technology Network UK. As chair she previously led the delivery of educational events for multidisciplinary diabetes teams and the development of a suite of national diabetes technology ‘best practice’ guides, in addition to online modules for people living with diabetes. Emma is an elected Association of British Clinical Diabetologists (ABCD) committee member and DAFNE structured education executive board member. She is a member of the National Diabetes Audit Insulin Pump Expert Reference Group and has also been involved in the #languagematters movement.

Presenter of 4 Presentations

 Conference Calendar
INDUSTRY SESSION

Insulin in the evolving experience of people living with diabetes

Date
Thu, 03.06.2021
Session Name
Plenary Industry Symposium 05 (Not Included In The Main Event CME/CPD Credit) (ID 84)
Lecture Time
14:10 - 14:25
Presenter
Authors
INDUSTRY SESSION

Q&A session

Date
Thu, 03.06.2021
Session Name
Plenary Industry Symposium 05 (Not Included In The Main Event CME/CPD Credit) (ID 84)
Lecture Time
15:15 - 15:25
Presenter
Authors
ORAL PRESENTATION SESSION

RISK FACTORS FOR DIABETES-RELATED DISTRESS IN PEOPLE LIVING WITH TYPE 1 DIABETES –LESSONS FROM THE ASSOCIATION OF BRITISH CLINICAL DIABETOLOGISTS (ABCD) FREESTYLE LIBRE AUDIT

Date
Sat, 05.06.2021
Session Name
0570 - Oral Presentation 15 (ID 74)
Lecture Time
16:35 - 16:45
Presenter
Authors

Abstract

Background and Aims

The objective of this study was to identify the baseline demographic and clinical characteristics associated with Diabetes-related distress in people living with Type 1 diabetes.

Methods

The study was performed using baseline data from the ABCD nationwide FreeStyle Libre audit. We collected diabetes-related distress scores at baseline with two items diabetes-related distress score (DDS) and follow up. An average item score of ≥3 (moderate distress) discriminated high from low-distressed subgroups. We used an unsupervised gradient boosting machine learning model (GBM) to identify the relative influence of baseline parameters on two components of DDS. The results of the GBM model were confirmed using linear regression analysis.

Results

The study consisted of 9124 people with Type 1 diabetes, with a mean age of 45.1(±15.3) years, 50.3% female, mean BMI of 26.5(±6.2) kg/m2 and mean baseline HbA1c 70.2(±18.3) mmol/mol. High diabetes-related distress was prevalent in 5476(60%) of people living with T1D at baseline. The two components of the DDS were significantly correlated (r2=0.73 P<0.0001). In the GBM model, baseline HbA1c (RI=51.4), GOLD score (RI=23.3), gender (RI=7.05) and fear of hypoglycaemia as an indication for starting on the FSL (RI=4.9) were associated with diabetes-related distress. The linear regression model confirmed that higher baseline HbA1c, higher GOLD score, female gender and fear of hypoglycaemia were significantly associated with DDS.

Conclusions

In this large UK cohort of people living with Type 1 diabetes, diabetes distress was prevalent and associated with high HbA1c, impaired awareness of hypoglycaemia and female gender.

Hide
PARALLEL SESSION

The effectiveness of isCGM: comparison of data from RCTs and routine-use

Date
Sat, 05.06.2021
Session Name
0540 - Live Q&A: Parallel Session 22: Continuous Glucose Sensors In Patients Using MDI (ID 60)
Lecture Time
16:27 - 16:47
Presenter
Authors

Abstract

Abstract Body

For decades finger prick self-monitoring of blood glucose (SMBG) has been the cornerstone of diabetes self-management, with the expectation that people with diabetes undertake SMBG at multiple points across the day to inform treatment decisions. Intermittently scanned continuous glucose monitoring (isCGM) has more recently become established as an alternative to finger prick SMBG. Individuals wear a sensor on the arm which is scanned with a reader, allowing the user to visualise the glucose information. This contrasts to real time CGM systems which allow direct visualisation of the data without the need to scan. Early randomised controlled trials highlighted the ability of isCGM to reduce hypoglycaemia in people living with Type 1 diabetes and Type 2 diabetes. The uptake of isCGM has since risen exponentially, largely replacing finger prick SMBG for many individuals living with diabetes. The latest generation of isCGM is now available with the additional benefit of optional alarms. A range of randomised controlled trials and real-world studies have been undertaken to explore the potential clinical benefits of the different generations of isCGM on outcomes, including HbA1c, hypoglycaemia and patient related outcome measures. This lecture will aim to review these studies and compare the findings of the randomised controlled trials with those of the published real-world data.

Hide